Huadong Pharmaceutical announced that Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received an acceptance notice issued by the State Drug Administration, and its self-developed application for the marketing license for the oral small molecule GLP-1 receptor agonist cavillerone trometriol tablets for long-term adult weight control was accepted. The registered classification is Class 1 chemical, with specifications containing 50 mg, 100 mg, and 200 mg. As of September 30, 2026, the company's total direct investment in R&D in this project was about 507 million yuan. The drug still needs to be reviewed by the Drug Review Center and can only be manufactured and sold after approval. There is uncertainty about the review and approval results.

Huadong Pharmaceutical announced that Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received an acceptance notice issued by the State Drug Administration, and its self-developed application for the marketing license for the oral small molecule GLP-1 receptor agonist cavillerone trometriol tablets for long-term adult weight control was accepted. The registered classification is Class 1 chemical, with specifications containing 50 mg, 100 mg, and 200 mg. As of September 30, 2026, the company's total direct investment in R&D in this project was about 507 million yuan. The drug still needs to be reviewed by the Drug Review Center and can only be manufactured and sold after approval. There is uncertainty about the review and approval results.